CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors

• Status: Recruiting
• Trial end date: 2023-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from CLDN18.2 targeting treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Cancer Hospital
• Treatments: Fluorodeoxyglucose F18

Criteria

Inclusion Criteria:

• 1. Aged >18 years old; ECOG 0 or 1;

• 2. Patients with solid tumors;

• 3. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);

• 4. life expectancy >=12 weeks.

Exclusion Criteria:

• 1. Significant hepatic or renal dysfunction;

• 2. Is pregnant or ready to pregnant;

• 3. Cannot keep their states for half an hour;

• 4. Refusal to join the clinical study;

• 5. Suffering from claustrophobia or other mental diseases;

• 6. Any other situation that researchers think it is not suitable to participate in the experiment.